{"id":"ribostamycin","rwe":[{"pmid":"41874382","year":"2026","title":"Identification and characteristics of a novel acquired aminoglycoside phosphotransferase, APH(3')-IVb, from Riemerella anatipestifer.","finding":"","journal":"Antimicrobial agents and chemotherapy","studyType":"Clinical Study"},{"pmid":"41631546","year":"2026","title":"Aminoglycosides, vancomycin, and metronidazole for people with cirrhosis and hepatic encephalopathy.","finding":"","journal":"The Cochrane database of systematic reviews","studyType":"Clinical Study"},{"pmid":"40864593","year":"2025","title":"8-Oxo-7,8-dihydropurines as Building Blocks to Enhance the Selectivity of an RNA Aptamer for Aminoglycosides.","finding":"","journal":"ACS chemical biology","studyType":"Clinical Study"},{"pmid":"40134786","year":"2025","title":"aac(6')-Iaq, a novel aminoglycoside acetyltransferase gene identified from an animal isolate Brucella intermedia DW0551.","finding":"","journal":"Frontiers in cellular and infection microbiology","studyType":"Clinical Study"},{"pmid":"40119290","year":"2025","title":"Identification of a novel aminoglycoside nucleotidyltransferase gene in Morganella morganii from farm sewage.","finding":"","journal":"BMC microbiology","studyType":"Clinical Study"}],"tags":[{"label":"ribostamycin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"J01GB10","category":"atc"},{"label":"Active","category":"status"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"vistamycin","offLabel":[],"synonyms":["ribostamycin sulfate","ribostamycin","hetangmycin","vistamycin","ribostamycin sulfate salt"],"timeline":[],"approvals":[],"brandName":"Vistamycin","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"ribostamycin","explanation":"Imagine your body's cells are like factories that make proteins to keep you healthy. Bacteria are like tiny factories that make proteins too, but they're bad for you. Vistamycin is like a special tool that blocks the bacteria's factories from making proteins, helping to stop the infection.","oneSentence":"Vistamycin works by binding to the 30S ribosomal subunit, inhibiting protein synthesis in bacteria.","technicalDetail":"Vistamycin binds to the 30S ribosomal subunit, preventing the formation of the 70S initiation complex and thereby inhibiting the initiation of protein synthesis in bacteria."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3526","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=RIBOSTAMYCIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:34:58.812583","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T10:58:47.311318+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"tobramycin","drugSlug":"tobramycin","fdaApproval":"1975-06-11","patentExpiry":"Sep 12, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"gentamicin","drugSlug":"gentamicin","fdaApproval":"1970-06-19","genericCount":36,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"kanamycin","drugSlug":"kanamycin","fdaApproval":"1973-02-13","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"neomycin","drugSlug":"neomycin","fdaApproval":"1957-03-26","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"amikacin","drugSlug":"amikacin","fdaApproval":"1981-01-22","patentExpiry":"May 15, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"netilmicin","drugSlug":"netilmicin","fdaApproval":"1983-02-28","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"plazomicin","drugSlug":"plazomicin","fdaApproval":"2018-06-25","patentExpiry":"Nov 21, 2028","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"ribostamycin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"tobramycin","brandName":"tobramycin","genericName":"tobramycin","approvalYear":"1975","relationship":"same-class"},{"drugId":"gentamicin","brandName":"gentamicin","genericName":"gentamicin","approvalYear":"1970","relationship":"same-class"},{"drugId":"kanamycin","brandName":"kanamycin","genericName":"kanamycin","approvalYear":"1973","relationship":"same-class"},{"drugId":"neomycin","brandName":"neomycin","genericName":"neomycin","approvalYear":"1957","relationship":"same-class"},{"drugId":"amikacin","brandName":"amikacin","genericName":"amikacin","approvalYear":"1981","relationship":"same-class"},{"drugId":"netilmicin","brandName":"netilmicin","genericName":"netilmicin","approvalYear":"1983","relationship":"same-class"},{"drugId":"plazomicin","brandName":"plazomicin","genericName":"plazomicin","approvalYear":"2018","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"010978","UNII":"2Q5JOU7T53","CHEBI":"CHEBI:65028","INN_ID":"3197","UMLSCUI":"C0035554","ChEMBL_ID":"CHEMBL221572","KEGG_DRUG":"D02209","DRUGBANK_ID":"DB03615","PDB_CHEM_ID":" RIO","PUBCHEM_CID":"33042","IUPHAR_LIGAND_ID":"12161","SECONDARY_CAS_RN":"53797-35-6","MESH_DESCRIPTOR_UI":"D012271"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"2.5 hours","clearance":"1.5 mL/min/kg","volumeOfDistribution":"0.25 L/kg"},"publicationCount":182,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"J01GB10","allCodes":["J01GB10"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 24","pmid":"41874382","title":"Identification and characteristics of a novel acquired aminoglycoside phosphotransferase, APH(3')-IVb, from Riemerella anatipestifer.","journal":"Antimicrobial agents and chemotherapy"},{"date":"2026 Feb 3","pmid":"41631546","title":"Aminoglycosides, vancomycin, and metronidazole for people with cirrhosis and hepatic encephalopathy.","journal":"The Cochrane database of systematic reviews"},{"date":"2025 Sep 19","pmid":"40864593","title":"8-Oxo-7,8-dihydropurines as Building Blocks to Enhance the Selectivity of an RNA Aptamer for Aminoglycosides.","journal":"ACS chemical biology"},{"date":"2025","pmid":"40134786","title":"aac(6')-Iaq, a novel aminoglycoside acetyltransferase gene identified from an animal isolate Brucella intermedia DW0551.","journal":"Frontiers in cellular and infection microbiology"},{"date":"2025 Mar 21","pmid":"40119290","title":"Identification of a novel aminoglycoside nucleotidyltransferase gene in Morganella morganii from farm sewage.","journal":"BMC microbiology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vistamycin, also known as Ribostamycin, is a small molecule antibiotic in the ribostamycin class. Its mechanism of action involves inhibiting protein synthesis in bacteria by binding to the 30S ribosomal subunit. However, due to the lack of available information, its target and approved indications are unknown. The commercial status of Vistamycin is also unclear, with no information available on its patent status or generic manufacturers. Further research is needed to determine its safety profile and potential uses.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T10:58:47.311318+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}